CGT and biotherapeutics consulting firm Dark Horse Consulting Group has acquired Massachusetts-based Converge Consulting.
Converge is known for its ability to bridge the gap between sound strategy and reliable execution for biopharma organizations in the areas of supply chain, manufacturing, commercial launch readiness, operational excellence, enterprise IT solutions, CMC and quality.
DHC — with operations in North America, Europe and APAC — is a fully integrated global consulting practice recognized for its depth of CGT expertise worldwide.
The buy expands on DHC’s 2024 acquisition of BioTechLogic, as the group continues to building a comprehensive ecosystem of integrated offerings across advanced therapies.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!